Regulatory requirements for orphan drugs and combination products MCQs With Answer

This quiz collection is designed for M.Pharm students preparing for the Regulatory Aspects of Drugs & Cosmetics (MRA201T) exam. It focuses on regulatory requirements for orphan drugs and combination products, clarifying key definitions, designation criteria, incentive mechanisms, submission pathways, and post‑market obligations. The questions are crafted to deepen understanding of orphan designation processes (US and EU), exclusivity periods, fee incentives, clinical trial considerations for rare diseases, and classification of combination products by primary mode of action and regulatory jurisdiction. Each MCQ includes clear options and the correct answer to help students test their knowledge, reinforce learning, and prepare effectively for university exams and regulatory practice.

Q1. Which of the following correctly defines the US criterion for orphan drug designation?

• A disease affecting fewer than 10,000 individuals worldwide
• A condition that affects fewer than 200,000 people in the United States
• A condition with no available therapies anywhere
• A disease with greater than 5% prevalence in the population

Correct Answer: A condition that affects fewer than 200,000 people in the United States

Q2. What is the duration of market exclusivity granted to an orphan drug in the United States upon approval?

• 5 years
• 7 years
• 10 years
• 12 years

Correct Answer: 7 years

Q3. In the European Union, which of the following best describes the prevalence threshold for orphan designation?

• Not more than 5 in 10,000 individuals
• Not more than 1 in 1,000 individuals
• Fewer than 200,000 people in the EU
• Any disease lacking a treatment option

Correct Answer: Not more than 5 in 10,000 individuals

Q4. Which regulatory incentive is commonly offered to sponsors of orphan drugs in both the US and EU?

• Mandatory price control by regulators
• Market exclusivity for a defined period
• Reduced clinical trial safety requirements
• Guaranteed reimbursement approval

Correct Answer: Market exclusivity for a defined period

Q5. Which office within the US FDA is primarily responsible for regulatory jurisdiction and assignment of combination products?

• Center for Drug Evaluation and Research (CDER)
• Office of Combination Products (OCP)
• Center for Devices and Radiological Health (CDRH)
• Center for Biologics Evaluation and Research (CBER)

Correct Answer: Office of Combination Products (OCP)

Q6. The primary mode of action (PMOA) of a combination product is important because it determines:

• The product’s wholesale distribution channels
• Which FDA center will have primary review responsibility
• The clinical trial endpoints to be ignored
• Whether the product is patentable

Correct Answer: Which FDA center will have primary review responsibility

Q7. For a combination product composed of a novel drug and a novel device, the most appropriate premarket submission to the FDA will usually be:

• An Abbreviated New Drug Application (ANDA)
• A Biologics License Application (BLA)
• A New Drug Application (NDA) or BLA depending on PMOA
• A 510(k) submission regardless of PMOA

Correct Answer: A New Drug Application (NDA) or BLA depending on PMOA

Q8. Which of the following is a typical regulatory benefit specifically offered to orphan drug sponsors in the EU?

• Guaranteed hospital formulary listing
• 10 years of market exclusivity
• Waiver of all clinical trial requirements
• Automatic approval without review

Correct Answer: 10 years of market exclusivity

Q9. Which pathway is commonly used in the US to seek approval for a drug that combines a previously approved active ingredient with a new delivery device?

• 505(b)(2) regulatory pathway
• ANDA pathway for generics
• Premarket Approval (PMA) for devices only
• Emergency Use Authorization only

Correct Answer: 505(b)(2) regulatory pathway

Q10. Which of these is NOT typically an incentive provided to orphan drug developers?

• Tax credits for clinical testing
• Priority review vouchers granted to all orphan approvals
• Fee waivers or reductions for regulatory submissions
• Scientific advice / protocol assistance from regulators

Correct Answer: Priority review vouchers granted to all orphan approvals

Q11. When assigning jurisdiction for a combination product, regulators determine the PMOA. If a product’s therapeutic effect is mainly produced by the device constituent, which center usually leads review?

• Center for Drug Evaluation and Research (CDER)
• Center for Devices and Radiological Health (CDRH)
• Office of Generic Drugs (OGD)
• Office of Combination Products only

Correct Answer: Center for Devices and Radiological Health (CDRH)

Q12. Orphan designation may be granted even if a disease affects more than the population threshold when:

• The sponsor commits to low pricing
• The product is intended for a subset of the disease population with distinct characteristics
• The drug has already been approved elsewhere
• The disease is chronic rather than acute

Correct Answer: The product is intended for a subset of the disease population with distinct characteristics

Q13. For combination products, which regulatory requirement is commonly applicable to the drug constituent regardless of device classification?

• Compliance with cGMP for pharmaceuticals
• 510(k) clearance for the drug
• Device user training mandated by FDA
• Exemption from adverse event reporting

Correct Answer: Compliance with cGMP for pharmaceuticals

Q14. Which of the following best describes a key post‑marketing obligation for orphan drugs?

• No further safety monitoring is required due to small populations
• Enhanced pharmacovigilance and potentially registries to monitor long‑term safety and effectiveness
• Automatic renewal of exclusivity every 5 years
• Mandatory conversion to generic status after 2 years

Correct Answer: Enhanced pharmacovigilance and potentially registries to monitor long‑term safety and effectiveness

Q15. Which regulatory document should a sponsor consult first to determine the classification and review pathway for a combination product with an unknown PMOA?

• FDA Guidance on Combination Products and PMOA
• International Council for Harmonisation (ICH) E6 only
• USP monographs for the drug substance
• Local hospital procurement policies

Correct Answer: FDA Guidance on Combination Products and PMOA

Q16. For orphan drug designation in the EU, one requirement is that the medical condition is life‑threatening or chronically debilitating. Which additional condition is required?

• The product must be cheaper than existing therapies
• There must be no satisfactory method of diagnosis, prevention or treatment, or the product must provide a significant benefit
• The sponsor must be a small or medium enterprise
• The product must be biologic in nature

Correct Answer: There must be no satisfactory method of diagnosis, prevention or treatment, or the product must provide a significant benefit

Q17. Which of the following is true regarding device-led combination products that include an active drug constituent?

• They always follow the drug regulatory pathway regardless of PMOA
• They are regulated as devices if the device achieves the primary mode of action
• The device constituent never requires GMP compliance
• They cannot obtain orphan designation

Correct Answer: They are regulated as devices if the device achieves the primary mode of action

Q18. Which expedited regulatory mechanism is often relevant for orphan drugs to accelerate development or review?

• Priority Review and Accelerated Approval (when criteria met)
• Mandatory 10-year review period for safety
• Automatic conditional approval without evidence
• Exemption from clinical trials

Correct Answer: Priority Review and Accelerated Approval (when criteria met)

Q19. What is an important consideration for labeling of combination products?

• Labeling only needs to describe the device constituent
• Labeling must address safe and effective use of all constituents and how they interact
• Labeling is optional for orphan combination products
• Only the drug’s INN should appear on the label

Correct Answer: Labeling must address safe and effective use of all constituents and how they interact

Q20. Which statement about fee incentives for orphan drugs is correct?

• Orphan drug sponsors never receive any fee reductions
• Both FDA and EMA may offer fee reductions or waivers for protocol assistance or regulatory fees to orphan sponsors
• Fee incentives are only available after full marketing approval
• Fee reductions automatically guarantee approval

Correct Answer: Both FDA and EMA may offer fee reductions or waivers for protocol assistance or regulatory fees to orphan sponsors

Download